Found: 14
Select item for more details and to access through your institution.
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-49286-x
- By:
- Publication type:
- Article
Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
- Published in:
- Science Translational Medicine, 2022, v. 14, n. 640, p. 1, doi. 10.1126/scitranslmed.abn2231
- By:
- Publication type:
- Article
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22115-1
- By:
- Publication type:
- Article
Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 1106, doi. 10.3390/cancers13051106
- By:
- Publication type:
- Article
Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1757, doi. 10.1093/neuonc/noaa126
- By:
- Publication type:
- Article
Oncolytic virus-derived type I interferon restricts CAR T cell therapy.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-17011-z
- By:
- Publication type:
- Article
Oncolytic virus-derived type I interferon restricts CAR T cell therapy.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-17011-z
- By:
- Publication type:
- Article
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-14568-7
- By:
- Publication type:
- Article
Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques.
- Published in:
- Molecular Therapy, 2015, v. 23, n. 6, p. 1066, doi. 10.1038/mt.2015.49
- By:
- Publication type:
- Article
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers.
- Published in:
- Molecular Therapy, 2012, v. 20, n. 4, p. 749, doi. 10.1038/mt.2011.276
- By:
- Publication type:
- Article
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
- Published in:
- Nature, 2011, v. 477, n. 7362, p. 99, doi. 10.1038/nature10358
- By:
- Publication type:
- Article
Targeting Tumor Vasculature With an Oncolytic Virus.
- Published in:
- Molecular Therapy, 2011, v. 19, n. 5, p. 886, doi. 10.1038/mt.2011.26
- By:
- Publication type:
- Article
Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity.
- Published in:
- Molecular Therapy, 2010, v. 18, n. 5, p. 896, doi. 10.1038/mt.2010.14
- By:
- Publication type:
- Article